Abstract
Human cell line models have been widely used for testing of novel anticancer compounds and for predicting clinical response to monotherapies and combinatorial therapies. For many years, standard monolayer culture conditions were used as gold standard, only surpassed by in vivo testing of mouse models. Recently, the incorporation of three-dimensional culture has been shown to further improve predictive compound testing. In view of the renewed interest in anti-RAS cancer therapy, we provide a protocol for establishing colorectal cancer organoids which are characterized by a high prevalence of KRAS mutations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Papke B, Der CJ (2017) Drugging RAS: know the enemy. Science 355(6330):1158–1163
Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP et al (2019) Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med 25(4):628–640
Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A et al (2019) Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med 25(4):620–627
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D et al (2019) The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781):217–223
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6(10):813–823
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603–607
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570–575
Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S et al (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141(5):1762–1772
Drost J, Clevers H (2018) Organoids in cancer research. Nat Rev Cancer 18(7):407–418
van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A et al (2015) Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161(4):933–945
Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK et al (2016) Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc 11(9):1724–1743
Schutte M, Risch T, Abdavi-Azar N, Boehnke K, Schumacher D, Keil M et al (2017) Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun 8:14262
Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV et al (2016) Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov 6(3):316–329
Schumacher D, Andrieux G, Boehnke K, Keil M, Silvestri A, Silvestrov M et al (2019) Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures. PLoS Genet 15(3):e1008076
Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K et al (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359(6378):920–926
Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF et al (2018) Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174(6):1586–1598.e1512
Cheng D, Tuveson D (2018) Kras in organoids. Cold Spring Harb Perspect Med 8(10)
Boehnke K, Iversen PW, Schumacher D, Lallena MJ, Haro R, Amat J et al (2016) Assay establishment and validation of a high-throughput screening platform for three-dimensional patient-derived colon cancer organoid cultures. J Biomol Screen 21(9):931–941
Schumacher D (2019) Genetic and phenotypic characterization of colorectal cancer 3D cell cultures and their application in preclinical research and precision medicine. PhD thesis, Humboldt University, Berlin
Acknowledgments
Our work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement no. 115234 (OncoTrack)) within EU FP7 and EFPIA companies’ in-kind contribution (www.imi.europa.eu) and by the German Cancer Consortium (DKTK).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Schumacher, D., Regan, J.L., Przybilla, D., Schäfer, R. (2021). Generation of Patient-Derived Colorectal Cancer Organoids for RAS Studies. In: Rubio, I., Prior, I. (eds) Ras Activity and Signaling. Methods in Molecular Biology, vol 2262. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1190-6_22
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1190-6_22
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1189-0
Online ISBN: 978-1-0716-1190-6
eBook Packages: Springer Protocols